Risk of subsequent colorectal cancers after a solid tumor in childhood: Effects of radiation therapy and chemotherapy.


Journal

Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624

Informations de publication

Date de publication:
02 2019
Historique:
received: 05 04 2018
revised: 14 09 2018
accepted: 18 09 2018
pubmed: 23 10 2018
medline: 7 11 2019
entrez: 23 10 2018
Statut: ppublish

Résumé

Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood cancer treatment. We aimed to quantify the roles of radiation therapy and chemotherapy agents in the occurrence of subsequent CRC. A nested case-control study was conducted using 36 CRC cases and 140 controls selected from 7032 five-year survivors of the French Childhood Cancer Survivor Study (FCCSS) cohort, treated from 1945 to 2000 in France. The radiation dose-distribution metrics at the site of CRC and doses of individual chemotherapeutic agents were calculated. Conditional logistic regressions were performed to calculate odds ratios (ORs). Overall, patients who received radiotherapy with estimated dose to colon had a 4.3-fold (95% CI, 1.3-17.6) increased risk for CRC compared with patients who did not receive radiotherapy, after adjustment for chemotherapy. This risk increased to 8.9-fold and 19.3-fold among patients who received radiation doses ranging from 20 to 29.99 Gy and ≥30 Gy, respectively. Our data reported a significantly elevated OR for anthracyclines, after controlling for radiotherapy and MOPP regimen. But, restricted analyses excluding patients who had received ≥30 Gy showed that only radiation doses ranging from 20 to 29.99 Gy produced a significant increase in subsequent CRC risk (OR = 7.8; 95% CI, 1.3-56.0), after controlling for anthracyclines and MOPP regimen. The risk of subsequent CRC was significantly increased after radiation dose (even < 30 Gy). This novel finding supports the need to update monitoring guidelines for CRC to optimize the long-term follow-up for subsequent CRC in survivors of childhood cancer.

Sections du résumé

BACKGROUND
Very few previous studies have addressed the question of colorectal cancer (CRC) after childhood cancer treatment. We aimed to quantify the roles of radiation therapy and chemotherapy agents in the occurrence of subsequent CRC.
METHODS
A nested case-control study was conducted using 36 CRC cases and 140 controls selected from 7032 five-year survivors of the French Childhood Cancer Survivor Study (FCCSS) cohort, treated from 1945 to 2000 in France. The radiation dose-distribution metrics at the site of CRC and doses of individual chemotherapeutic agents were calculated. Conditional logistic regressions were performed to calculate odds ratios (ORs).
RESULTS
Overall, patients who received radiotherapy with estimated dose to colon had a 4.3-fold (95% CI, 1.3-17.6) increased risk for CRC compared with patients who did not receive radiotherapy, after adjustment for chemotherapy. This risk increased to 8.9-fold and 19.3-fold among patients who received radiation doses ranging from 20 to 29.99 Gy and ≥30 Gy, respectively. Our data reported a significantly elevated OR for anthracyclines, after controlling for radiotherapy and MOPP regimen. But, restricted analyses excluding patients who had received ≥30 Gy showed that only radiation doses ranging from 20 to 29.99 Gy produced a significant increase in subsequent CRC risk (OR = 7.8; 95% CI, 1.3-56.0), after controlling for anthracyclines and MOPP regimen.
CONCLUSIONS
The risk of subsequent CRC was significantly increased after radiation dose (even < 30 Gy). This novel finding supports the need to update monitoring guidelines for CRC to optimize the long-term follow-up for subsequent CRC in survivors of childhood cancer.

Identifiants

pubmed: 30345604
doi: 10.1002/pbc.27495
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Historical Article Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e27495

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Rodrigue S Allodji (RS)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Nadia Haddy (N)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Giao Vu-Bezin (G)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Agnès Dumas (A)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Brice Fresneau (B)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Université Paris-Saclay, Department of Pediatric Oncology, F-94805 Villejuif, France.

Imene Mansouri (I)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Charlotte Demoor-Goldschmidt (C)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.
Chu Angers, Pediatric Oncology, F-49933 Angers, France.

Chiraz El-Fayech (C)

Gustave Roussy, Université Paris-Saclay, Department of Pediatric Oncology, F-94805 Villejuif, France.

Hélène Pacquement (H)

Institut Curie, Paris 75005, France.

Martine Munzer (M)

Institut Jean Godinot, F-51092 Reims, France.

Pierre-Yves Bondiau (PY)

Centre Antoine Lacassagne, F-06100 Nice, France.

Delphine Berchery (D)

Centre Claudius Régaud, F-31300 Toulouse, France.

Odile Oberlin (O)

Gustave Roussy, Université Paris-Saclay, Department of Pediatric Oncology, F-94805 Villejuif, France.

Carole Rubino (C)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Ibrahima Diallo (I)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Florent de Vathaire (F)

Université Paris-Saclay, Univ. Paris-Sud, UVSQ, CESP, Cancer and Radiation Team, Villejuif, France.
INSERM, CESP, Cancer and Radiation Team, F-94805 Villejuif, France.
Gustave Roussy, Department of Clinical Research, Cancer and Radiation Team, F-94805 Villejuif, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH